- Home
- Medical news & Guidelines
- Anesthesiology
- Cardiology and CTVS
- Critical Care
- Dentistry
- Dermatology
- Diabetes and Endocrinology
- ENT
- Gastroenterology
- Medicine
- Nephrology
- Neurology
- Obstretics-Gynaecology
- Oncology
- Ophthalmology
- Orthopaedics
- Pediatrics-Neonatology
- Psychiatry
- Pulmonology
- Radiology
- Surgery
- Urology
- Laboratory Medicine
- Diet
- Nursing
- Paramedical
- Physiotherapy
- Health news
- Fact Check
- Bone Health Fact Check
- Brain Health Fact Check
- Cancer Related Fact Check
- Child Care Fact Check
- Dental and oral health fact check
- Diabetes and metabolic health fact check
- Diet and Nutrition Fact Check
- Eye and ENT Care Fact Check
- Fitness fact check
- Gut health fact check
- Heart health fact check
- Kidney health fact check
- Medical education fact check
- Men's health fact check
- Respiratory fact check
- Skin and hair care fact check
- Vaccine and Immunization fact check
- Women's health fact check
- AYUSH
- State News
- Andaman and Nicobar Islands
- Andhra Pradesh
- Arunachal Pradesh
- Assam
- Bihar
- Chandigarh
- Chattisgarh
- Dadra and Nagar Haveli
- Daman and Diu
- Delhi
- Goa
- Gujarat
- Haryana
- Himachal Pradesh
- Jammu & Kashmir
- Jharkhand
- Karnataka
- Kerala
- Ladakh
- Lakshadweep
- Madhya Pradesh
- Maharashtra
- Manipur
- Meghalaya
- Mizoram
- Nagaland
- Odisha
- Puducherry
- Punjab
- Rajasthan
- Sikkim
- Tamil Nadu
- Telangana
- Tripura
- Uttar Pradesh
- Uttrakhand
- West Bengal
- Medical Education
- Industry
Topical tacrolimus as effective as corticosteroids for atopic dermatitis in kids: Study
Finland: A new study conducted by A. Salava and team noted that the application of tacrolimus 0.03% and 0.1% ointments and topical corticosteroids (low and moderate potency) is safe in young children with moderate-to-severe atopic dermatitis. Also, they both have comparable efficacy and safety profiles. However, evidence on children under long-term therapy seemed to be inadequate.
The findings of this study were published in the journal Clinical and Experimental Dermatology on 19th November 2021.
Topical tacrolimus has been used as off-label medication in young children but data regarding children under 2 years of age and long-term treatment remains limited. To fill this knowledge gap, the researchers aimed to evaluate the safety of tacrolimus 0.03 percent and 0.1 percent ointments compared to corticosteroids in young children with atopic dermatitis.
An elaborate 36-month follow-up study was undertaken with 152 young children aged one to three years old who had moderate-to-severe atopic dermatitis. Children were prospectively monitored, and data on infections, illness severity, growth characteristics, immunization reactions, and other relevant laboratory tests were collected thoroughly.
The results stated that skin-related illnesses, other infections, growth metrics height and weight, EASI scores, vaccine reactions, serum cortisol levels, and serum levels of IL-4, IL-10, IL-12, IL-31, and IFN gamma did not change between treatment groups. In both groups, EASI reduced dramatically.
And in the 1-week of visit, nine patients (11.68 percent) in the tacrolimus group showed significantly detectable tacrolimus blood concentrations. During the trial, no tumours or serious infections were discovered. Additionally, the levels of eosinophils in the blood were comparable in both groups.
Finally, this study data has contributed on extending the knowledge on Tacrolimus use on children under 2 years of age. Also for the long-term treatment and safety limits of the same.
Reference:
Salava, A., Perälä, M., Pelkonen, A., Mäkelä, M. and Remitz, A. (2021), Safety of tacrolimus 0.03% and 0.1% ointments in young children with atopic dermatitis - a 36-month follow-up study. Clinical and Experimental Dermatology. Accepted Author Manuscript. https://doi.org/10.1111/ced.15024
Medical Dialogues consists of a team of passionate medical/scientific writers, led by doctors and healthcare researchers. Our team efforts to bring you updated and timely news about the important happenings of the medical and healthcare sector. Our editorial team can be reached at editorial@medicaldialogues.in.
Dr Kamal Kant Kohli-MBBS, DTCD- a chest specialist with more than 30 years of practice and a flair for writing clinical articles, Dr Kamal Kant Kohli joined Medical Dialogues as a Chief Editor of Medical News. Besides writing articles, as an editor, he proofreads and verifies all the medical content published on Medical Dialogues including those coming from journals, studies,medical conferences,guidelines etc. Email: drkohli@medicaldialogues.in. Contact no. 011-43720751